Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of your joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.
An autoimmune disorder, rheumatoid arthritis occurs when your immune system mistakenly attacks your own body's tissues. In addition to causing joint problems, rheumatoid arthritis sometimes can affect other organs of the body — such as the skin, eyes, lungs and blood vessels.
Although rheumatoid arthritis can occur at any age, it usually begins after age 40. The disorder is much more common in women than in men. Treatment focuses on controlling symptoms and preventing joint damage.
RA is a life-long disease with no current cure available. ARG301 uses a unique method to address RA and may offer an effective way to treat this disease. This treatment appears to be applicable to about 50% of RA suffers. In a market believed to approach 7.3 million people in the leading pharmaceutical markets (2), the market for rheumatic anti- inflammatory drugs are profitable and expected to increase due to new treatment launches. Worldwide RA therapeutics revenue has been projected to increase to $80.7 billion in 2020.
Due to the size of the market RA has been targeted by many pharmaceutical companies; however, an effective and safe orally administered treatment should be an attractive treatment for both patients and pharmaceutical companies. ARG301 is orally administrated and appears to have a good safety profile and to offer an attractive treatment in the RA market.
arGentis' treatment, ARG301, utilizes a modified peptide ligand to treat the disease. The first in man, Phase I clinical trail, has been completed. There are issued patents in the US and EU.
AutoImmune Disease Treatments